TMSP(SH:600671)2021-04-29 16:00Financial Performance - Operating revenue for the period was CNY 38,914,225.39, representing a decline of 30.16% year-on-year[5] - Net profit attributable to shareholders was a loss of CNY 5,558,845.64, compared to a loss of CNY 3,170,341.37 in the same period last year[5] - The weighted average return on net assets was -4.3038%, compared to -0.0233% in the same period last year[5] - Basic and diluted earnings per share were both -CNY 0.0252, compared to -CNY 0.0002 in the previous year[5] - Total revenue for Q1 2021 was ¥38,914,225.39, a decrease of 30.2% compared to ¥55,721,624.55 in Q1 2020[49] - Net loss for Q1 2021 was ¥3,353,092.51, compared to a net loss of ¥351,748.20 in Q1 2020, indicating a significant increase in losses[50] - Operating profit for Q1 2021 was -¥5,663,210.18, worsening from -¥3,489,814.96 in Q1 2020[50] - The company's operating revenue for Q1 2021 was CNY 777,971.11, a significant decrease from CNY 17,245,832.71 in Q1 2020, representing a decline of approximately 95.5%[52] - The net profit for Q1 2021 was a loss of CNY 1,423,679.93, compared to a profit of CNY 431,573.56 in Q1 2020, indicating a negative swing of 429.5%[53] Assets and Liabilities - Total assets at the end of the reporting period were CNY 440,790,500.68, a decrease of 0.39% compared to the end of the previous year[5] - The company's total assets decreased to ¥279,495,533.36 as of March 31, 2021, down from ¥284,282,044.64 at the end of 2020[46] - The company's current assets totaled RMB 225.39 million as of March 31, 2021, compared to RMB 222.92 million at the end of 2020, indicating a marginal increase[41] - The total liabilities of the company were RMB 350.81 million as of March 31, 2021, compared to RMB 349.18 million at the end of 2020, showing a slight increase[42] - Total liabilities decreased slightly to ¥196,662,126.51 in Q1 2021 from ¥200,024,957.86 in Q4 2020[46] Cash Flow - The net cash flow from operating activities was a negative CNY 1,311,785.21, compared to a negative CNY 326,267.54 in the previous year[5] - The cash flow from operating activities for Q1 2021 was a net outflow of CNY 1,311,785.21, worsening from a net outflow of CNY 326,267.54 in Q1 2020[56] - The cash inflow from financing activities in Q1 2021 was CNY 106,840,000.00, an increase from CNY 95,000,000.00 in Q1 2020[57] - The cash and cash equivalents at the end of Q1 2021 were CNY 3,118,803.70, down from CNY 19,889,615.27 at the end of Q1 2020, reflecting a decrease of approximately 84.3%[57] - The company reported a net decrease in cash and cash equivalents of -$1,299,632.10 during the quarter[59] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,366[11] - The top shareholder, Qingdao Huilong Huaze Investment Co., Ltd., held 22.01% of the shares, totaling 26,799,460 shares[11] Investments and Contracts - The company invested 14 million yuan in the establishment of Xishuangbanna Great Wall Health Industry Park, holding a 9.33% stake in the registered capital[14] - A major engineering contract worth 60 million yuan was signed by the company's subsidiary, exceeding 50% of the company's net assets, with a prepayment of 30.73 million yuan already made[16] - The company plans to acquire 100% equity of Xixia Medicine Health Base for a preliminary price of 55 million yuan, which also exceeds 50% of the latest audited net assets[16] Legal Matters - The company has initiated legal proceedings to recover 30.73 million yuan in engineering prepayments and 54.14 million yuan in equity transfer payments[18] - The company has initiated legal proceedings to recover RMB 460 million from Qingfeng Yuansheng, with a court ruling requiring repayment and interest compensation of RMB 264,857.77[32] - The company has confirmed a non-operating fund occupation of RMB 3,073.12 million related to the construction contract with Gongxiang Lanzhou Branch, which has not progressed despite payments[26] - The company has been involved in multiple instances of providing guarantees for related party loans without board approval, totaling RMB 331 million in outstanding guarantees as of December 31, 2020[31] Government Support - The company received government subsidies amounting to CNY 2,436,207.47, which are included in the non-operating income[9] Production and Compliance - The company has completed the GMP renovation for two production lines and is in the process of obtaining the necessary production licenses[21] - The company is required to complete the consistency evaluation for its main product, Amoxicillin Clavulanate Potassium Tablets, by the end of 2021 to continue production and sales[22] Investigations - The company is currently under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, which may pose risks to its stock listing status[36]